<SEC-DOCUMENT>0001558370-21-001179.txt : 20210218
<SEC-HEADER>0001558370-21-001179.hdr.sgml : 20210218
<ACCEPTANCE-DATETIME>20210218072030
ACCESSION NUMBER:		0001558370-21-001179
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210217
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210218
DATE AS OF CHANGE:		20210218

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Generation Bio Co.
		CENTRAL INDEX KEY:			0001733294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				814301281
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39319
		FILM NUMBER:		21647664

	BUSINESS ADDRESS:	
		STREET 1:		301 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		857-529-5908

	MAIL ADDRESS:	
		STREET 1:		301 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tmb-20210217x8k.htm
<DESCRIPTION>8-K
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.9.1.77--><!--Created on: 2/18/2021 12:20:23 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><font style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><font style="font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-size:12pt;font-weight:bold;">WASHINGTON, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:5.0pt;margin-bottom:5pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1.5" width="25.0%" style="background-color:#000000;color:#000000;height:1.5pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-size:18pt;font-weight:bold;">FORM&#160;8-K</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:5.0pt;margin-bottom:5pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1.5" width="25.0%" style="background-color:#000000;color:#000000;height:1.5pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-size:12pt;font-weight:bold;">of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Date of report (Date of earliest event reported): February&#160;17, 2021</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:5.0pt;margin-bottom:5pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1.5" width="25.0%" style="background-color:#000000;color:#000000;height:1.5pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:24pt;font-weight:bold;">Generation Bio Co.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">(Exact Name of Registrant as Specified in Charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:5.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1.5" width="25.0%" style="background-color:#000000;color:#000000;height:1.5pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:32.06%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Delaware</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.91%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:32.05%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">001-39319</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.9%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:32.05%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">81-4301284</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.06%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(State or Other Jurisdiction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of Incorporation)</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.91%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:32.05%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Commission</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File Number)</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.9%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:32.05%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(IRS&#160;Employer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification&#160;No.)</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">301 Binney Street</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cambridge, MA</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.83%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:49.07%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">02142&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Address of Principal Executive Offices)</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.83%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49.07%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">Registrant&#8217;s telephone number, including area code: (617) 655-7500</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Not applicable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">(Former Name or Former Address, if Changed Since Last Report)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:5.0pt;margin-bottom:5pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1.5" width="25.0%" style="background-color:#000000;color:#000000;height:1.5pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i style="font-style:italic;">see</i> General Instruction A.2. below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 0.25pt;"><font style="display:inline-block;width:22.3pt;"><font style="color:#000000;font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9744;</font></font>Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 0.25pt;"><font style="display:inline-block;width:22.3pt;"><font style="color:#000000;font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9744;</font></font>Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 0.25pt;"><font style="display:inline-block;width:22.3pt;"><font style="color:#000000;font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9744;</font></font>Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 0.25pt;"><font style="display:inline-block;width:22.3pt;"><font style="color:#000000;font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9744;</font></font>Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:31.99%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:32%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:32%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:32%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:32%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:31.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Common Stock, $0.0001 par value per share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">GBIO</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Nasdaq Global Select Market</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">Emerging growth company&#160;&#160;&#9746;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;&#9744;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-indent:0pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><font style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="font-size:12pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-indent:0pt;margin:0pt;"><font style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:4.47%;margin-right:4.47%;margin-top:30pt;page-break-after:always;width:91.06%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;5.02&#160;&#160;&#160;&#160;&#160;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On February 17, 2021, upon the recommendation of the Nominating and Corporate Governance Committee, the Board of Directors (&#8220;Board&#8221;) of Generation Bio Co. (the &#8220;Company&#8221;) increased the size of the Board from eight (8) to nine (9) members, and effective March 1, 2021, appointed Ron Cooper to fill the newly created vacancy as a Class II director, with a term of office to continue until the Company&#8217;s 2022 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Mr. Cooper will receive compensation as a non-employee director in accordance with the Company&#8217;s non-employee director compensation program that the Board approved in February 2021 (the &#8220;Program&#8221;). Pursuant to the Program, Mr. Cooper will be entitled to receive a cash retainer of $40,000 per year for his service on the Board. This retainer is payable in arrears in four equal quarterly installments on the last day of each quarter, provided that the amount of such payment will be prorated for the first quarter of 2021. In addition, under the Program, Mr. Cooper will receive an initial grant of an option to purchase 30,000 shares of the Company&#8217;s common stock under the Company&#8217;s 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;) that will vest <font style="background-color:#ffffff;">monthly over a three-year period</font>, subject to Mr. Cooper&#8217;s continued service as a director through each applicable vesting date. The option grant will have an exercise price equal to the closing sales price of the Company&#8217;s common stock on March 1, 2021 as reported on The Nasdaq Global Select Market and a term of 10 years, subject to earlier termination for cessation of continuous service. Further, under the Program, on the date of each annual meeting of stockholders commencing in 2022, Mr. Cooper will be entitled to receive an option to purchase 15,000 shares of the Company&#8217;s common stock under the 2020 Plan that will vest in full on the earlier of the first anniversary of the grant date and the date of the annual meeting of stockholders in the year immediately following the year in which the option was granted, will be issued at an exercise price equal to the closing sales price of the Company&#8217;s common stock as reported on The Nasdaq Global Select Market on the date of grant and will have a term of ten years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In conjunction with Mr. Cooper&#8217;s appointment, the Company and Mr. Cooper entered into the Company&#8217;s standard indemnification agreement, a copy of which was filed as Exhibit 10.10 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-238608) filed with the Securities and Exchange Commission on May 22, 2020. Pursuant to the terms of the indemnification agreement, the Company may be required, among other things, to indemnify Mr.&#160;Cooper for certain expenses, including attorneys&#8217; fees, judgments, fines and settlement amounts incurred by him in any action or proceeding arising out of his service as one of our members of the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A copy of the Company&#8217;s press release announcing Mr. Cooper&#8217;s election, dated February 18, 2021, is attached hereto as Exhibit 99.1 and is hereby incorporated by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9.01 Financial Statements and Exhibits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(d)&#160;Exhibits</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><br><b style="font-weight:bold;">No.</b></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:89.63%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.54%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:89.63%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="tmb-20210217xex99d1.htm"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Press Release Issued by Generation Bio Co. on February&#160;18, 2021</font></a> </p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:99.25%;"><tr><td style="vertical-align:top;width:49.66%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50.33%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GENERATION BIO CO.</p></td></tr><tr><td style="vertical-align:top;width:49.66%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:bottom;width:50.33%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;width:49.66%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: February&#160;18, 2021</p></td><td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45.81%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Geoff McDonough</p></td></tr><tr><td style="vertical-align:top;width:49.66%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:45.81%;border-top:1px solid #000000;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Geoff McDonough, M.D.</p></td></tr><tr><td style="vertical-align:top;width:49.66%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:45.81%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Chief Executive Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tmb-20210217xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.9.1.77--><!--Created on: 2/18/2021 12:20:17 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><div style="height:0pt;position:relative;width:100%;"><div style="height:28.5pt;left:0.06%;max-width:99.94%;position:absolute;top:-29.55pt;width:148.85pt;z-index:-9223372036603117568;"><div style="height:28.3pt;left:0pt;padding-bottom:0.2pt;position:relative;top:0pt;width:148.85pt;"><img src="tmb-20210217xex99d1001.jpg" alt="Graphic" style="height:28.3pt;width:148.85pt;"></div></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;text-align:right;margin:0pt;"><font style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;text-align:right;margin:0pt;"><font style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;min-height:28.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;">Generation Bio Appoints Ron Cooper to its Board of Directors</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">CAMBRIDGE, MASS., February 18, 2021 -- </b><font style="font-family:'Times New Roman','Times','serif';">Generation Bio Co</font><font style="font-family:'Times New Roman','Times','serif';">. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, announced today that Ron Cooper has been appointed to its Board of Directors. The appointment is effective March 1, 2021. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Ron Cooper is a global biopharmaceutical executive who currently serves as president, chief executive officer and board member of Albireo Pharma, Inc., a position he has held since June 2015. He has successfully matured Albireo Pharma, Inc. to a clinical-stage public company on the verge of its first drug approval. Prior to joining Albireo Pharma, Inc., Cooper had a 25-year career at Bristol Myers Squibb, during which time he held multiple leadership roles in sales, marketing and general management, culminating in his role as president of Europe. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;We are excited to welcome Ron to our Board of Directors during this critical stage of Generation Bio&#8217;s evolution,&#8221; said Geoff McDonough, M.D., president and chief executive officer of Generation Bio. &#8220;Ron is a highly seasoned and respected life sciences executive, and we look forward to his expertise, engagement and assistance as we advance our work toward the clinic. His global commercial experience and current work in rare diseases will be a great addition to our Board and organization as a whole.&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;First generation gene therapy has both great promise and limitations. Generation Bio&#8217;s unique non-viral platform has the potential to significantly expand the reach of gene therapy through redosing and scale,&#8221; Cooper stated. &#8220;I look forward to joining the Board of this dynamic and growing company that could have a positive impact on patients.&#8221; </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">About Generation Bio</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:14pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Generation Bio&#160;is an innovative genetic medicines company focused on creating a new class of non-viral gene therapy to provide durable, redosable treatments for people living with rare and prevalent diseases. The company&#8217;s non-viral platform incorporates a proprietary, high-capacity DNA construct called closed-ended DNA, or ceDNA; a cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The platform is designed to enable multi-year durability from a single dose of ceDNA and to allow titration and redosing if needed. The ctLNP is designed to deliver large genetic payloads, including multiple genes, to specific tissues to address a wide range of indications. The company&#8217;s efficient, scalable manufacturing process supports Generation Bio&#8217;s mission to extend the reach of gene therapy to more people, living with more diseases, in more places around the world.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:14pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">For more information, please visit </font><font style="font-family:'Times New Roman','Times','serif';">www.generationbio.com</font><font style="font-family:'Times New Roman','Times','serif';">.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:14pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Forward-Looking Statements</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:14pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Any statements in this press release about future expectations, plans and prospects for the Company, including statements about our strategic plans or objectives, our technology platforms, our research and clinical development plans, and other statements containing the words </font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:14pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;">&#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;plans,&#8221; &#8220;expects,&#8221; and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.  Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the conduct of research activities, the initiation and completion of preclinical studies and clinical trials and clinical development of the Company&#8217;s product candidates; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials; expectations for regulatory approvals to conduct trials or to market products; challenges in the manufacture of genetic medicine products; the Company&#8217;s ability to obtain sufficient cash resources to fund the Company&#8217;s foreseeable and unforeseeable operating expenses and capital expenditure requirements; and the impact of the COVID-19 pandemic on the Company&#8217;s business and operations; as well as the other risks and uncertainties set forth in the &#8220;Risk Factors&#8221; section of our most recent quarterly report on Form 10-Q, which is on file with the Securities and Exchange Commission, and in subsequent filings the Company may make with the Securities and Exchange Commission.  In addition, the forward-looking statements included in this press release represent the Company&#8217;s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company&#8217;s views to change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company&#8217;s views as of any date subsequent to the date on which they were made.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><b style="color:#262626;font-family:'Times New Roman','Times','serif';font-weight:bold;">Contacts:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="color:#262626;font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><b style="color:#262626;font-family:'Times New Roman','Times','serif';font-weight:bold;">Investors</b><font style="color:#262626;font-family:'Times New Roman','Times','serif';"><br></font><font style="font-family:'Times New Roman','Times','serif';">Maren Killackey<br>Generation Bio<br>541-646-2420<br></font><font style="font-family:'Times New Roman','Times','serif';">mkillackey@generationbio.com</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Media</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Alicia Webb</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Generation Bio</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">847-254-4275</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">awebb@generationbio.com</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Stephanie Simon</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Ten Bridge Communications</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="color:#262626;font-family:'Times New Roman','Times','serif';">617-581-9333</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="color:#262626;font-family:'Times New Roman','Times','serif';text-decoration:none;">stephanie@tenbridgecommunications.com</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tmb-20210217xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20210217xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Y 2H# 2(  A$! Q$!_\0
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M:7YX^G&._M^'2O6E&U%7.<#&30FV%&I4G*2G&R6WF+14$M[:P-MEN88V]'D
M-21S13+NBD1U]58$4S>Z'T4UW2-2SLJJ.I)P*9]HA\HR>='L'5MPP/QH'<EH
MJ&&[MK@D0W$4A'4(X/\ *IJ O<9++'#&9)75$7JS' %$4T<\8DBD61#T93D'
M\:S?$G_( NO]T?S%0^%V5- B+$ ;FY)]ZR=1^UY/*Y'/[_+Y&W14:7$,APDJ
M,?0,#4E:WN61I-'([(DB,R\, P)'UJ2L+2-"33=0GN%NC+N!4+CD<YYYY-;I
M( R3BH@Y-7DK$Q;:U045%]I@W8\Z//IN%2U=[E!11D>M% '#?$GQ5-H.F1VE
MB^R\NLXD'6-!U(]ST_.O/-!\":UXJMSJ)F2*%R=LEPQ)?W'4UM_&)&&KZ=)@
M[# PS[[J] \$WMM>^$M/:U*[8XA&R@_=8=0:SMS2LSR)4UB<5*%1Z+9'C'B+
M3->\-HFE7\[FU9O,B*.2A/3(]/I7H7@75TTCX:7&I7)+)!+(<9ZG( 'XD@?C
M53XPWEN;33[+>#<AS*4'4+C&?S_E61;V\T_P4N3"QQ'>>9(H_B4,!^A(/X5.
MTM#&*]AB)J#O:+,ZSMM?^)&LS,]SLACY<DD1Q ] !W/'Z58U_P  :KX3L_[4
MM+_SHXB"[Q QLG/7KTK,\(^&KSQ&;F.QU..UDAP6C9F!8'N,=0#Q^(]:Z5_A
M7KKH5DUN)E/4,SX-"5UL94Z4JM/GY&V^MSI/ _BN;Q#X=NX;QMU[:H0[XQO4
M@X;Z\&O)-%.K76I+::9++]HN08_E;&0>O->H^"_!\OA^/4+XZC;7<5Q;,B&W
M.5XZG/X5Q_PK /C6/(Z0R8_*F[Z7-*L:D_8QJ:/7]"'Q!\/]7\.Z=_:<L\4T
M:D>88F.Y"?7(]:[GX9^)I]0T6[M[^5I'L &\QN24(.,GOC!K>\?#_BAM5_ZY
M#_T(5YO\.X9;G1/%4,)(D>T"J1ZD/3MRRT-?9K#8J,:>S3T^\K:CK&M?$#Q%
M]@LG=+8L?*B!PJJ/XF]:O:C\*-4TZP>[L[Y+B:-2QB1"C<?W3GD_E7*>&=(F
MUO5OL-O?)9S,A*LY(W8_AX_SQ7:_\*MU_P#Z#D?_ 'T]2E?6QRTHRKQ<Y0<F
M^M]B_P##/QE<:A*VBZC*9)0FZWE8Y9@.JGUXY^@-<'K-Y>V_C6^DLY9!<"[<
M1E3DY)P,5W7A#X?7&C^)8=1.J6EPMJ761(220Q0C!]#SFN4@57^*P5@"/[1/
M!^M#O97-*JK>QIQJ:.]CI_#7@#5--UBUU[5;V$>26EE0L2WW3U/3OGK7)ZOK
M&K^._$0M;4R&)W*V\"G"JOJ?PY)KV[Q!!+<^&M4@@4M+):2HBCJ6*$ 5X[\*
M[RVM/&)6X=4:>W:&(MTW[E./Q"G_ ":;5K(UQ%&-.4*$7:,GJ3W'PX\1Z%:_
MVE9W<;S1#>4MV8.,>G'-97@R[N;KX@6$T\SM++.S2'/4E6)KWRZN8;2TEN)Y
M%2&-2SLQX %>!^#I(YOB+82Q)LC>Y=D3^Z"&(%$HI-6)Q.'A0JTU![O87QQX
M;OM"U'[1=S1R1WLTKQ;&)( (/.?]X5/H?P_UG7-(@U&TN8$@EW;59R",,0>W
MJ*Z7XR_ZO1?K/_[)74_#4C_A ].Y[R_^C&H45S6%'"4Y8N=-[)7_ "/&+RPO
M-#\2?V?<39GMY4RR,<9.#Q^=>I?$GQC<:)#%ING/LNYUWO*.L:9[>Y_0?@1P
M?CC_ )*1>_\ 7:+_ - 2K/Q4@DB\9O*Z_NY849#Z@#!_4&ELG8R4Y4:=50[V
M_,;H_P /-=\1V@U&:X2%)?F1KEF+/[]^*K2#Q%\.]9C!D*@_, &+13+W&/\
M)%>VZ!>6U]H5G<6KJT+1*!M[8&"/PKSSXQ7ENR:=9K(K7"LTC*.JJ< 9IN*2
MNCHK82G1H^U@_>77N7_'6KQZO\-8=1MF9%GEC)7/(ZY!_&N \-:)KGBF*73[
M.Y,=G&WF2F1R$#$8[=3Q6[=020?!2V\S/SW@=?H6-=!\'0/[!U XY-U_[(*-
MVKDN/UC$04^L5<X#6=$UCP-JL#?:-KGYXIH6(#8KW#PSJQUOP]97[ !Y8_G
MZ;AP:X7XR#_1M*/^W)_(5T?PU_Y$BR^K_P#H1IQTDT;X6/L<5.E':W^1L^)/
M^0!=?[H_F*YG1=,NM8ME26=XK*(D )U8GDUTWB3_ ) %U_NC^8JMX2D1M%"J
M1N1R&&:YZD%.ND^QVSBI54GV*-YX16"$S:?<3><O(#D<_3 &*O>&M6DU"U>&
MX.;B'@G^\/6MUF55+,0 !DDUR/A8B76=0FC7$1SCVRW%-P5*K'DZ] <5":Y>
MI+X<)_M_5LDD!VZ_[QJ"^NKS7]6;3[24QV\>=S#OCJ3_ (5-X>YU[5_]]O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
2HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
